SCHEMBL5257673

SCHEMBL5257673

Fc1ccc(-c2scc(C3=CC4CCCN4CC3)c2-c2ccncc2)cc1

nearest known ligand 0.68

Predicted protein targets (top 4)

geneUniProtsupporting neighboursconfidence
MAPK14 Q16539 10/20 0.68
MAPK11 Q15759 3/20 0.68
KDM4E B2RXH2 1/20 0.33
AR P10275 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5257670 1.00 MAPK14 (0.68) MAPK14MAPK11KDM4EAR
SCHEMBL5849687 0.81 MAPK14 (1.00) MAPK14MAPK11
SCHEMBL5249915 0.78 MAPK14 (0.43) MAPK14MAPK11
SCHEMBL5249909 0.78 MAPK14 (0.43) MAPK14MAPK11
SCHEMBL5850059 0.78 MAPK14 (0.94) MAPK14MAPK11
SCHEMBL5251156 0.76 MAPK14 (0.70) MAPK14MAPK11
SCHEMBL5249678 0.76 MAPK14 (0.62) MAPK14MAPK11
SCHEMBL5248650 0.76 MAPK14 (0.70) MAPK14MAPK11
SCHEMBL5247627 0.76 MAPK14 (0.62) MAPK14MAPK11
SCHEMBL5850060 0.73 MAPK11 (0.80) MAPK14MAPK11

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1361225-B1 COMPOUNDS SUBSTITUTED WITH BICYCLIC AMINO GROUPS SANKYO CO (JP) 2007-11-07 EP disclosed
US-7091352-B2 Compounds substituted with bicyclic amino groups SANKYO COMPANY, LIMITED (JP) 2006-08-15 US disclosed
US-20040147525-A1 Compounds substituted with bicyclic amino groups SANKYO COMPANY, LIMITED (JP) 2004-07-29 US disclosed
EP-1361225-A1 COMPOUNDS SUBSTITUTED WITH BICYCLIC AMINO GROUPS Sankyo Company, Limited (JP) 2003-11-12 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040147525-A1 Compounds substituted with bicyclic amino groups IL2, IL1B, IL4I1 MAPK14 1355/4885MAPK11 1447/4885KDM4E 3358/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.